TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB | Market Closed - Deutsche Boerse AG 03:36:04 2024-06-28 pm EDT | ||
| 10.62 EUR | +4.63% |
|
| Current month | +32.92% | ||
| 1 month | +30.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 10.62 | +4.63% |
| 24-06-27 | 10.15 | +1.40% |
| 24-06-26 | 10.01 | +2.25% |
| 24-06-25 | 9.79 | +0.62% |
| 24-06-24 | 9.73 | -0.61% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 03:36 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW88XZ |
| ISIN | DE000SW88XZ5 |
| Date issued | 2024-04-19 |
| Strike | 2,530 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.79 € |
|---|---|
| Lowest since issue | 6.4 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,745
DKK
Average target price
2,464
DKK
Spread / Average Target
+41.20%
- Stock Market
- Certificates
- Certificat
